key: cord-0749890-w37x04bo
authors: Sobol, Irina; Yuzefpolskaya, Melana; Roth, Zachary; Colombo, Paolo C.; Horn, Evelyn; Takeda, Koji; Sayer, Gabriel; Uriel, Nir; Naka, Yoshifumi
title: Characteristics and Outcomes of LVAD patients with COVID-19
date: 2020-09-19
journal: J Card Fail
DOI: 10.1016/j.cardfail.2020.09.011
sha: 2c65b5c7969c233626a233ecd15682f2e506eccf
doc_id: 749890
cord_uid: w37x04bo

nan

The pandemic of coronavirus disease 2019 has afflicted >4 million people in the US and carries a high mortality rate. Preexisting cardiovascular diseases such as coronary artery disease(CAD), hypertension(HTN), diabetes mellitus(DM) and older age have been associated with an increased risk of COVID-19. 1 Thromboembolic events are common during COVID-19 infection, and the approach to both prophylactic and therapeutic anticoagulation is not clear 2 .

Patients with left ventricular assist devices (LVAD) might represent a particularly vulnerable patient population, due to presence of multiple co-morbidities, relatively immunocompromised state and an elevated inflammatory profile. 3 In addition, these patients are at an increased risk of thromboembolic events such as stroke and pump thrombosis, requiring maintenance antithrombotic therapy. Preliminary case reports have not indicated a disproportionate impact of COVID-19 on the LVAD population. 4 The goal of this series was to share our experience with patients with LVADs who were diagnosed with COVID-19, with particular emphasis on their initial presentation, disease course, treatment management and final outcome.

We retrospectively reviewed all adult patients with LVADs who are presently followed at two large centers in New York City. Only patients diagnosed with COVID-19 through polymerase chain reaction analysis were included in the study and followed through August 5th, 2020.

Baseline characteristics, echocardiographic and laboratory data were extracted using electronic medical records. This study was approved by the Institutional Review Boards of both centers.

Among the 190 patients with LVADs followed by our centers, we have identified 6 patients (3.1%) who were diagnosed COVID-19. Low prevalence of diagnosed disease may be explained by limited testing. One suspected patient had sudden death at home but was never tested due to mild symptomatology. The number of negative tests performed is not available for analysis.

Patients' age range was 30-79 years, 4 were male, time on LVAD ranged from 1 day to 6.8 years [ Table 1 ].

Patients' co-morbidities included: HTN (4/6), DM (2/6), obesity (1/6), and end-stage renal disease requiring dialysis (1/6). One patient with Fontan circulation with hypoplastic right ventricle and superimposed acute lymphocytic myocarditis predating COVID pandemic, was transitioned from temporary support to permanent device during the index hospitalization. The initial presentation of COVID-19 included dyspnea and cough (4/6), fever (2/6) and diarrhea (1/6). Four patients were admitted to the hospital and 3 required care in the intensive care unit.

Laboratory results are summarized in Table 1 . All patients had lymphopenia, and elevations of troponin. Ferritin levels ranged from 59 ng/mL to 1623 ng/mL and D-Dimer was greater than 1 ug/L in 3 patients. In 2 patients with an echocardiogram during the present admission, no changes in left ventricular ejection fraction or left ventricular end-diastolic dimension were noted.

Supplemental oxygen was required in all but 1 hospitalized patient, and 2 patients required intubation. None of the patients underwent prone positioning. One patient required denovo dialysis. During hospitalization, heparin was administered in 2 patients, and 1 patient was transitioned from heparin to argatroban with suspected Fontan related thrombus on echocardiogram. One patient who had not previously been anticoagulated, due to history of bleeding, was started on subcutaneous enoxaparin at discharge. Three patients were on chronic aspirin therapy, and it was discontinued in one of them. Hydroxychloroquine was given to 3 patients, high-dose corticosteroids to 2 patients and an interleukin-1 (IL-1) antagonist was administered to 1 patient due to severe cytokine storm. None of the patients received an interleukin -6 (IL-6) receptor antagonist. There were no occurrences of neurologic events, bleeding events or right ventricular failure (RVF) during the disease course. Two patients died during the index hospitalization: one due to profound hypoxemia from COVID-19 pneumonia [ Figure S1 .], leading to asystolic arrest and the second due to cytokine storm and suspected Fontan thrombosis. The other four patients recovered completely. All surviving patients were followed for a range of 1.5 to 5 months. The known manifestations of COVID-19 lead to special considerations in the LVAD population.

These include propensity for thromboembolic events and risk of developing RVF. Even though we have not encountered this in our small case series, high index of suspicion was maintained.

Use of prone positioning might be of concern in an LVAD population owing to the risk of driveline damage, outflow graft compression and worsening of RV hemodynamics due to increased thoracic pressure and impaired venous return.

In conclusion, patients with LVADs represent a vulnerable population at high risk for significant complications associated with COVID-19 disease, their management can be particularly challenging and requires a multi-specialty approach.

Paolo Colombo serves as an Abbott Consultant without honoraria and received an Abbott 

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

ArticlePubMedGoogle Scholar

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Quantitative changes in T-cell populations after left ventricular assist device implantation: relationship to T-cell apoptosis and soluble CD95

The Imperfect Cytokine Storm: Severe COVID-19 with ARDS in Patient on Durable LVAD Support

Prone Positioning in Severe Acute Respiratory Distress Syndrome